Research programme: apoptosis stimulants - Myrexis
Alternative Names: EP128265; EP90745 series; MPI-0441138; MX90745 seriesLatest Information Update: 26 Nov 2012
At a glance
- Originator EpiCept Corporation
- Developer Myrexis
- Class Antineoplastics; Quinazolines; Small molecules
- Mechanism of Action Apoptosis stimulants; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer